Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-8-10
pubmed:abstractText
S-1 is an attractive oral fluorouracil antitumor drug, which is being called "a self-rescuing drug". This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Phase I and an early phase II clinical trials were performed about ten years ago, and these results had already been introduced to the Journal "Clinical Cancer Research Vol. 5, pages 2000-2005, 1999". The data of this article in this journal was referred from the results of the figures and tables based on the above trial. Most of the authors in this article have contributed on that pharmacokinetics study and published the above manuscripts. In that study, the pharmacokinetics of 5-FU, intact FT, CDHP and Oxo after administration of the standard dose of S-1 had been performed. These studies were carried out at two hospitals, Department of Surgery (Section 1) Sapporo Medical University and Chemotherapy Cancer Center, Cancer Institute Hospital and Japanese Foundation for Cancer Research (Ohtsuka). The number of patients accepted for this trial is twelve, 5 patients with gastric cancer, 4 with colorectal cancer and 3 with breast cancer. Single administration trial was referred to all patients, but consecutive administration trial was limited to ten patients. The results of plasma concentration, Cmax, Tmax, AUC0-14, and T1/2 of 5-FU, FT, CDHP, and Oxo were ascertained in details. It was a surprise that the indicated data was very similar to that of the intravenous 5-FU continuous infusion. Therefore, the low dose administration of 5-FU (FT) as S-1 may result in good antitumor effects with minimum adverse effects to the patients.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
33 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-35
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:16897969-Administration, Oral, pubmed-meshheading:16897969-Adult, pubmed-meshheading:16897969-Aged, pubmed-meshheading:16897969-Animals, pubmed-meshheading:16897969-Antimetabolites, Antineoplastic, pubmed-meshheading:16897969-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16897969-Dihydrouracil Dehydrogenase (NADP), pubmed-meshheading:16897969-Drug Combinations, pubmed-meshheading:16897969-Female, pubmed-meshheading:16897969-Fluorouracil, pubmed-meshheading:16897969-Humans, pubmed-meshheading:16897969-Kidney, pubmed-meshheading:16897969-Male, pubmed-meshheading:16897969-Middle Aged, pubmed-meshheading:16897969-Neoplasms, pubmed-meshheading:16897969-Oxonic Acid, pubmed-meshheading:16897969-Rats, pubmed-meshheading:16897969-Tegafur, pubmed-meshheading:16897969-Uracil
pubmed:year
2006
pubmed:articleTitle
[Pharmacokinetics of S-1].
pubmed:affiliation
Dept of Surgery (Section 1), Sapporo Medical University, Japan.
pubmed:publicationType
Journal Article, English Abstract, Review